Stifel Nicolaus Initiates/Restarts BIIB, AFFY, CELG, GILD, ACOR, ARQL, ARIA, EXEL, BSTC at Buy, AMGN, DNDN at Hold

March 15, 2012 7:48 AM EDT Send to a Friend
Get Alerts BIIB Hot Sheet
Price: $303.55 +1.49%

Rating Summary:
    21 Buy, 8 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade BIIB Now!
Join SI Premium – FREE
Stifel Nicolaus' Joel Sendek initiated and resumed coverage on the following Biotech and Drug stocks Thursday morning:
  • Biogen (Nasdaq: BIIB) with a Buy rating and a $144 price target
  • Affymax (Nasdaq: AFFY) with a Buy rating and a $19 price target
  • Celgene (Nasdaq: CELG) with a Buy rating and a $87 price target
  • Gilead (Nasdaq: GILD) with a Buy rating and a $57 price target
  • Acorda Therapeutics (Nasdaq: ACOR) with a Buy rating and a $34 price target
  • ArQule (Nasdaq: ARQL) with a Buy rating and a $13 price target
  • Ariad Pharma (Nasdaq: ARIA) with a Buy rating and a $19 price target
  • Exelixis (Nasdaq: EXEL) with a Buy rating and a $8 price target
  • BioSpecifics Technologies (Nasdaq: BSTC) with a Buy rating and a $ price target
  • Amgen (Nasdaq: AMGN) with a Hold rating
  • Dendreon (Nasdaq: DNDN) with a Hold rating
Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Stifel Nicolaus

Add Your Comment